United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
“Congratulations to the dedicated Unitherians who worked tirelessly to help us achieve our third straight quarter and second straight year of record revenue,” said
“Our commercial business remains a solid foundation supporting our innovative and revolutionary efforts to cure end stage organ disease,” said
Fourth Quarter and Full Year 2023 Financial Results
Key financial highlights include (in millions, except per share data):
|
Three Months Ended
|
|
Year Ended
|
||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
||||
Total revenues |
$ |
614.7 |
|
$ |
491.5 |
|
$ |
2,327.5 |
|
$ |
1,936.3 |
Net income |
$ |
217.1 |
|
$ |
132.1 |
|
$ |
984.8 |
|
$ |
727.3 |
Net income, per basic share |
$ |
4.62 |
|
$ |
2.88 |
|
$ |
21.04 |
|
$ |
15.98 |
Net income, per diluted share |
$ |
4.36 |
|
$ |
2.67 |
|
$ |
19.81 |
|
$ |
15.00 |
Revenues
The table below presents the components of total revenues (dollars in millions):
|
Three Months Ended
|
|
Dollar Change |
|
Percentage Change |
|
Year Ended
|
|
Dollar Change |
|
Percentage Change |
||||||||||
|
|
2023 |
|
|
2022 |
|
|
|
|
2023 |
|
|
2022 |
|
|
||||||
Net product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Tyvaso DPI®(1) |
$ |
213.7 |
|
$ |
92.2 |
|
$ |
121.5 |
|
132% |
|
$ |
731.1 |
|
$ |
158.3 |
|
$ |
572.8 |
|
362% |
Nebulized Tyvaso®(1) |
|
136.9 |
|
|
150.1 |
|
|
(13.2) |
|
(9)% |
|
|
502.6 |
|
|
714.7 |
|
|
(212.1) |
|
(30)% |
Total Tyvaso |
|
350.6 |
|
|
242.3 |
|
|
108.3 |
|
45% |
|
|
1,233.7 |
|
|
873.0 |
|
|
360.7 |
|
41% |
Remodulin®(2) |
|
115.1 |
|
|
122.5 |
|
|
(7.4) |
|
(6)% |
|
|
494.8 |
|
|
500.2 |
|
|
(5.4) |
|
(1)% |
Orenitram® |
|
84.1 |
|
|
75.8 |
|
|
8.3 |
|
11% |
|
|
359.4 |
|
|
325.1 |
|
|
34.3 |
|
11% |
Unituxin® |
|
54.2 |
|
|
36.7 |
|
|
17.5 |
|
48% |
|
|
198.9 |
|
|
182.9 |
|
|
16.0 |
|
9% |
Adcirca® |
|
6.8 |
|
|
10.4 |
|
|
(3.6) |
|
(35)% |
|
|
28.9 |
|
|
41.3 |
|
|
(12.4) |
|
(30)% |
Other |
|
3.9 |
|
|
3.8 |
|
|
0.1 |
|
3% |
|
|
11.8 |
|
|
13.8 |
|
|
(2.0) |
|
(14)% |
Total revenues |
$ |
614.7 |
|
$ |
491.5 |
|
$ |
123.2 |
|
25% |
|
$ |
2,327.5 |
|
$ |
1,936.3 |
|
$ |
391.2 |
|
20% |
(1) |
Net product sales include both the drug product and the respective inhalation device. |
(2) |
Net product sales include sales of infusion devices including the Remunity® Pump. |
Fourth Quarter 2023 Compared to Fourth Quarter 2022. Total Tyvaso revenues grew by 45% to
Full Year 2023 Compared to Full Year 2022. Total Tyvaso revenues grew by 41% to
The table below presents the breakdown of total revenues between
|
Three Months Ended |
|
Year Ended |
||||||||||||||||||||||||
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||||||||||||||
|
|
ROW |
Total |
|
|
ROW |
Total |
|
|
ROW |
Total |
|
|
ROW |
Total |
||||||||||||
Net product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Tyvaso DPI(1) |
$ |
213.7 |
$ |
— |
$ |
213.7 |
|
$ |
92.2 |
$ |
— |
$ |
92.2 |
|
$ |
731.1 |
$ |
— |
$ |
731.1 |
|
$ |
158.3 |
$ |
— |
$ |
158.3 |
Nebulized Tyvaso(1) |
|
123.7 |
|
13.2 |
|
136.9 |
|
|
148.4 |
|
1.7 |
|
150.1 |
|
|
477.1 |
|
25.5 |
|
502.6 |
|
|
708.6 |
|
6.1 |
|
714.7 |
Total Tyvaso |
|
337.4 |
|
13.2 |
|
350.6 |
|
|
240.6 |
|
1.7 |
|
242.3 |
|
|
1,208.2 |
|
25.5 |
|
1,233.7 |
|
|
866.9 |
|
6.1 |
|
873.0 |
Remodulin(2) |
|
106.3 |
|
8.8 |
|
115.1 |
|
|
97.7 |
|
24.8 |
|
122.5 |
|
|
414.6 |
|
80.2 |
|
494.8 |
|
|
407.5 |
|
92.7 |
|
500.2 |
Orenitram |
|
84.1 |
|
— |
|
84.1 |
|
|
75.8 |
|
— |
|
75.8 |
|
|
359.4 |
|
— |
|
359.4 |
|
|
325.1 |
|
— |
|
325.1 |
Unituxin |
|
48.7 |
|
5.5 |
|
54.2 |
|
|
36.4 |
|
0.3 |
|
36.7 |
|
|
181.3 |
|
17.6 |
|
198.9 |
|
|
170.5 |
|
12.4 |
|
182.9 |
Adcirca |
|
6.8 |
|
— |
|
6.8 |
|
|
10.4 |
|
— |
|
10.4 |
|
|
28.9 |
|
— |
|
28.9 |
|
|
41.3 |
|
— |
|
41.3 |
Other |
|
2.6 |
|
1.3 |
|
3.9 |
|
|
2.8 |
|
1.0 |
|
3.8 |
|
|
9.8 |
|
2.0 |
|
11.8 |
|
|
2.8 |
|
11.0 |
|
13.8 |
Total revenues |
$ |
585.9 |
$ |
28.8 |
$ |
614.7 |
|
$ |
463.7 |
$ |
27.8 |
$ |
491.5 |
|
$ |
2,202.2 |
$ |
125.3 |
$ |
2,327.5 |
|
$ |
1,814.1 |
$ |
122.2 |
$ |
1,936.3 |
(1) |
Net product sales include both the drug product and the respective inhalation device. |
(2) |
Net product sales include sales of infusion devices including the Remunity Pump. |
Expenses
Cost of sales. The table below summarizes cost of sales by major category (dollars in millions):
|
Three Months Ended
|
|
Dollar Change |
|
Percentage Change |
|
Year Ended
|
|
Dollar Change |
|
Percentage Change |
||||||||||
|
|
2023 |
|
|
2022 |
|
|
|
|
2023 |
|
|
2022 |
|
|
||||||
Category: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Cost of sales |
$ |
70.1 |
|
$ |
55.9 |
|
$ |
14.2 |
|
25% |
|
$ |
255.1 |
|
$ |
146.7 |
|
$ |
108.4 |
|
74% |
Share-based compensation expense(1) |
|
0.9 |
|
|
2.9 |
|
|
(2.0) |
|
(69)% |
|
|
2.4 |
|
|
4.9 |
|
|
(2.5) |
|
(51)% |
Total cost of sales |
$ |
71.0 |
|
$ |
58.8 |
|
$ |
12.2 |
|
21% |
|
$ |
257.5 |
|
$ |
151.6 |
|
$ |
105.9 |
|
70% |
(1) |
See Share-based compensation below. |
Cost of sales, excluding share-based compensation. The increase in cost of sales for the quarter ended
The increase in cost of sales for the year ended
Research and development expense. The table below summarizes the nature of research and development expense by major expense category (dollars in millions):
|
Three Months Ended
|
|
Dollar Change |
|
Percentage Change |
|
Year Ended
|
|
Dollar Change |
|
Percentage Change |
|||||||||||||
|
|
2023 |
|
|
2022 |
|
|
|
|
2023 |
|
|
2022 |
|
|
|||||||||
Category: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
External research and development(1) |
$ |
50.4 |
|
$ |
46.7 |
|
$ |
3.7 |
|
8% |
|
$ |
192.0 |
|
$ |
168.8 |
|
$ |
23.2 |
|
|
14% |
||
Internal research and development(2) |
|
43.2 |
|
|
35.4 |
|
|
7.8 |
|
22% |
|
|
146.6 |
|
|
131.4 |
|
|
15.2 |
|
|
12% |
||
Share-based compensation expense(3) |
|
5.7 |
|
|
11.0 |
|
|
(5.3) |
|
(48)% |
|
|
15.6 |
|
|
23.8 |
|
|
(8.2 |
) |
|
(34)% |
||
Impairments(4) |
|
— |
|
|
— |
|
|
— |
|
—% |
|
|
— |
|
|
— |
|
|
— |
|
|
—% |
||
Other(5) |
|
52.1 |
|
|
0.8 |
|
|
51.3 |
|
NM(6) |
|
|
53.8 |
|
|
(1.1) |
|
|
54.9 |
|
|
NM(6) |
||
Total research and development expense |
$ |
151.4 |
|
$ |
93.9 |
|
$ |
57.5 |
|
61% |
|
$ |
408.0 |
|
$ |
322.9 |
|
$ |
85.1 |
|
|
26% |
(1) |
External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before FDA approval of the relevant product. |
(2) |
Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before FDA approval, and internal facilities-related expenses, including depreciation, related to research and development activities. |
(3) |
See Share-based compensation below. |
(4) |
Impairments primarily includes impairment charges to write down the carrying value of in-process research and development (IPR&D) and of certain property, plant, and equipment as a result of research and development activities. There were no impairment charges during the years ended |
(5) |
Other primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products, adjustments to the fair value of our contingent consideration obligations, and costs to acquire certain IPR&D assets. During the quarter and year ended |
(6) |
Calculation is not meaningful. |
Research and development, excluding share-based compensation. The increase in research and development expense for the quarter ended
The increase in research and development expense for the year ended
Selling, general, and administrative expense. The table below summarizes selling, general, and administrative expense by major category (dollars in millions):
|
Three Months Ended
|
|
Dollar Change |
|
Percentage Change |
|
Year Ended
|
|
Dollar Change |
|
Percentage Change |
||||||||||
|
|
2023 |
|
|
2022 |
|
|
|
|
2023 |
|
|
2022 |
|
|
||||||
Category: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
General and administrative |
$ |
98.1 |
|
$ |
89.3 |
|
$ |
8.8 |
|
10% |
|
$ |
374.2 |
|
$ |
333.2 |
|
$ |
41.0 |
|
12% |
Sales and marketing |
|
24.1 |
|
|
23.0 |
|
|
1.1 |
|
5% |
|
|
81.8 |
|
|
70.8 |
|
|
11.0 |
|
16% |
Share-based compensation expense(1) |
|
10.0 |
|
|
50.9 |
|
|
(40.9) |
|
(80)% |
|
|
21.1 |
|
|
78.1 |
|
|
(57.0) |
|
(73)% |
Total selling, general, and administrative expense |
$ |
132.2 |
|
$ |
163.2 |
|
$ |
(31.0) |
|
(19)% |
|
$ |
477.1 |
|
$ |
482.1 |
|
$ |
(5.0) |
|
(1)% |
(1) |
See Share-based compensation below. |
General and administrative, excluding share-based compensation. The increase in general and administrative expense for the year ended
Sales and marketing, excluding share-based compensation. The increase in sales and marketing expense for the year ended
Share-based compensation. The table below summarizes share-based compensation expense by major category (dollars in millions):
|
Three Months Ended
|
|
Dollar Change |
|
Percentage Change |
|
Year Ended
|
|
Dollar Change |
|
Percentage Change |
|||||||||||
|
|
2023 |
|
|
2022 |
|
|
|
|
2023 |
|
|
|
2022 |
|
|
||||||
Category: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Stock options |
$ |
2.9 |
|
$ |
5.8 |
|
$ |
(2.9) |
|
(50)% |
|
$ |
15.4 |
|
|
$ |
22.6 |
|
$ |
(7.2) |
|
(32)% |
Restricted stock units |
|
14.1 |
|
|
12.1 |
|
|
2.0 |
|
17% |
|
|
52.4 |
|
|
|
35.7 |
|
|
16.7 |
|
47% |
Share tracking awards plan (STAP) |
|
(0.9) |
|
|
46.5 |
|
|
(47.4) |
|
(102)% |
|
|
(30.7 |
) |
|
|
46.7 |
|
|
(77.4) |
|
(166)% |
Employee stock purchase plan |
|
0.5 |
|
|
0.4 |
|
|
0.1 |
|
25% |
|
|
2.0 |
|
|
|
1.8 |
|
|
0.2 |
|
11% |
Total share-based compensation expense |
$ |
16.6 |
|
$ |
64.8 |
|
$ |
(48.2) |
|
(74)% |
|
$ |
39.1 |
|
|
$ |
106.8 |
|
$ |
(67.7) |
|
(63)% |
The decrease in share-based compensation expense for the quarter ended
Other expense, net. The change in other expense, net for the year ended
Income tax expense. Income tax expense was
Inducement Restricted Stock Units
On
Webcast
We will host a webcast to discuss our fourth quarter and full year 2023 financial results on
At
You can learn more about what it means to be a PBC here: unither.com/pbc.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our future growth expectations from both our current commercial operations and our pipeline; our organ manufacturing programs, including our efforts to cure end-stage organ disease and the anticipated clinical trials of miroliverELAP and our xenotransplantation program; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the
MIROLIVERELAP, ORENITRAM, REMODULIN, REMUNITY, TYVASO, TYVASO DPI, and UNITUXIN are registered trademarks of
ADCIRCA is a registered trademark of Eli Lilly and Company.
CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share data) |
|||||||||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
(Unaudited) |
|
|
|
|
||||||||||
Total revenues |
$ |
614.7 |
|
|
$ |
491.5 |
|
|
$ |
2,327.5 |
|
|
$ |
1,936.3 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Cost of sales |
|
71.0 |
|
|
|
58.8 |
|
|
|
257.5 |
|
|
|
151.6 |
|
Research and development |
|
151.4 |
|
|
|
93.9 |
|
|
|
408.0 |
|
|
|
322.9 |
|
Selling, general, and administrative |
|
132.2 |
|
|
|
163.2 |
|
|
|
477.1 |
|
|
|
482.1 |
|
Total operating expenses |
|
354.6 |
|
|
|
315.9 |
|
|
|
1,142.6 |
|
|
|
956.6 |
|
Operating income |
|
260.1 |
|
|
|
175.6 |
|
|
|
1,184.9 |
|
|
|
979.7 |
|
Interest income |
|
51.0 |
|
|
|
20.8 |
|
|
|
162.7 |
|
|
|
45.2 |
|
Interest expense |
|
(15.1 |
) |
|
|
(12.3 |
) |
|
|
(59.3 |
) |
|
|
(32.4 |
) |
Other expense, net |
|
(0.6 |
) |
|
|
(5.3 |
) |
|
|
(14.0 |
) |
|
|
(40.2 |
) |
Impairment of investment in privately-held company |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1.7 |
) |
Total other income (expense), net |
|
35.3 |
|
|
|
3.2 |
|
|
|
89.4 |
|
|
|
(29.1 |
) |
Income before income taxes |
|
295.4 |
|
|
|
178.8 |
|
|
|
1,274.3 |
|
|
|
950.6 |
|
Income tax expense |
|
(78.3 |
) |
|
|
(46.7 |
) |
|
|
(289.5 |
) |
|
|
(223.3 |
) |
Net income |
$ |
217.1 |
|
|
$ |
132.1 |
|
|
$ |
984.8 |
|
|
$ |
727.3 |
|
Net income per common share: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
4.62 |
|
|
$ |
2.88 |
|
|
$ |
21.04 |
|
|
$ |
15.98 |
|
Diluted |
$ |
4.36 |
|
|
$ |
2.67 |
|
|
$ |
19.81 |
|
|
$ |
15.00 |
|
Weighted average number of common shares outstanding: |
|
|
|
|
|
|
|
||||||||
Basic |
|
47.0 |
|
|
|
45.8 |
|
|
|
46.8 |
|
|
|
45.5 |
|
Diluted |
|
49.8 |
|
|
|
49.4 |
|
|
|
49.7 |
|
|
|
48.5 |
|
SELECTED CONSOLIDATED BALANCE SHEET DATA (In millions) |
|||||
|
|
||||
|
|
2023 |
|
|
2022 |
Cash, cash equivalents, and marketable investments |
$ |
4,903.9 |
|
$ |
4,154.9 |
Total assets |
|
7,167.0 |
|
|
6,044.5 |
Total liabilities |
|
1,182.2 |
|
|
1,247.8 |
Total stockholders' equity |
|
5,984.8 |
|
|
4,796.7 |
The table below presents the breakdown of select historical total revenues between
|
Three Months Ended |
|||||||||||||||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
|
ROW |
Total |
|
ROW |
Total |
|
ROW |
Total |
|
ROW |
Total |
||||||||||||||||||||||||
Net product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Tyvaso DPI(1) |
$ |
118.7 |
$ |
— |
$ |
118.7 |
$ |
193.6 |
$ |
— |
$ |
193.6 |
$ |
205.1 |
$ |
— |
$ |
205.1 |
$ |
213.7 |
$ |
— |
$ |
213.7 |
||||||||||||
Nebulized Tyvaso(1) |
|
115.7 |
|
4.0 |
|
119.7 |
|
119.6 |
|
5.7 |
|
125.3 |
|
118.1 |
|
2.6 |
|
120.7 |
|
123.7 |
|
13.2 |
|
136.9 |
||||||||||||
Total Tyvaso |
|
234.4 |
|
4.0 |
|
238.4 |
|
313.2 |
|
5.7 |
|
318.9 |
|
323.2 |
|
2.6 |
|
325.8 |
|
337.4 |
|
13.2 |
|
350.6 |
||||||||||||
Remodulin(2) |
|
93.2 |
|
28.2 |
|
121.4 |
|
103.5 |
|
23.7 |
|
127.2 |
|
111.6 |
|
19.5 |
|
131.1 |
|
106.3 |
|
8.8 |
|
115.1 |
||||||||||||
Orenitram |
|
88.2 |
|
— |
|
88.2 |
|
95.1 |
|
— |
|
95.1 |
|
92.0 |
|
— |
|
92.0 |
|
84.1 |
|
— |
|
84.1 |
||||||||||||
Unituxin |
|
44.3 |
|
4.8 |
|
49.1 |
|
39.5 |
|
4.8 |
|
44.3 |
|
48.8 |
|
2.5 |
|
51.3 |
|
48.7 |
|
5.5 |
|
54.2 |
||||||||||||
Adcirca |
|
7.3 |
|
— |
|
7.3 |
|
7.5 |
|
— |
|
7.5 |
|
7.3 |
|
— |
|
7.3 |
|
6.8 |
|
— |
|
6.8 |
||||||||||||
Other |
|
2.3 |
|
0.2 |
|
2.5 |
|
3.2 |
|
0.3 |
|
3.5 |
|
1.7 |
|
0.2 |
|
1.9 |
|
2.6 |
|
1.3 |
|
3.9 |
||||||||||||
Total revenues |
$ |
469.7 |
$ |
37.2 |
$ |
506.9 |
$ |
562.0 |
$ |
34.5 |
$ |
596.5 |
$ |
584.6 |
$ |
24.8 |
$ |
609.4 |
$ |
585.9 |
$ |
28.8 |
$ |
614.7 |
|
Three Months Ended |
|||||||||||||||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
|
ROW |
Total |
|
ROW |
Total |
|
ROW |
Total |
|
ROW |
Total |
||||||||||||||||||||||||
Net product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Tyvaso DPI(1) |
$ |
— |
$ |
— |
$ |
— |
$ |
3.0 |
$ |
— |
$ |
3.0 |
$ |
63.1 |
$ |
— |
$ |
63.1 |
$ |
92.2 |
$ |
— |
$ |
92.2 |
||||||||||||
Nebulized Tyvaso(1) |
|
170.1 |
|
1.9 |
|
172.0 |
|
196.2 |
|
1.8 |
|
198.0 |
|
193.9 |
|
0.7 |
|
194.6 |
|
148.4 |
|
1.7 |
|
150.1 |
||||||||||||
Total Tyvaso |
|
170.1 |
|
1.9 |
|
172.0 |
|
199.2 |
|
1.8 |
|
201.0 |
|
257.0 |
|
0.7 |
|
257.7 |
|
240.6 |
|
1.7 |
|
242.3 |
||||||||||||
Remodulin(2) |
|
99.1 |
|
32.6 |
|
131.7 |
|
108.5 |
|
23.5 |
|
132.0 |
|
102.2 |
|
11.8 |
|
114.0 |
|
97.7 |
|
24.8 |
|
122.5 |
||||||||||||
Orenitram |
|
82.8 |
|
— |
|
82.8 |
|
79.0 |
|
— |
|
79.0 |
|
87.5 |
|
— |
|
87.5 |
|
75.8 |
|
— |
|
75.8 |
||||||||||||
Unituxin |
|
48.0 |
|
7.6 |
|
55.6 |
|
43.3 |
|
1.2 |
|
44.5 |
|
42.8 |
|
3.3 |
|
46.1 |
|
36.4 |
|
0.3 |
|
36.7 |
||||||||||||
Adcirca |
|
9.8 |
|
— |
|
9.8 |
|
10.4 |
|
— |
|
10.4 |
|
10.7 |
|
— |
|
10.7 |
|
10.4 |
|
— |
|
10.4 |
||||||||||||
Other |
|
— |
|
10.0 |
|
10.0 |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
2.8 |
|
1.0 |
|
3.8 |
||||||||||||
Total revenues |
$ |
409.8 |
$ |
52.1 |
$ |
461.9 |
$ |
440.4 |
$ |
26.5 |
$ |
466.9 |
$ |
500.2 |
$ |
15.8 |
$ |
516.0 |
$ |
463.7 |
$ |
27.8 |
$ |
491.5 |
|
Three Months Ended |
|||||||||||||||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
|
ROW |
Total |
|
ROW |
Total |
|
ROW |
Total |
|
ROW |
Total |
||||||||||||||||||||||||
Net product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Tyvaso DPI(1) |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
||||||||||||
Nebulized Tyvaso(1) |
|
122.4 |
|
0.6 |
|
123.0 |
|
152.6 |
|
1.2 |
|
153.8 |
|
160.7 |
|
3.5 |
|
164.2 |
|
165.0 |
|
1.5 |
|
166.5 |
||||||||||||
Total Tyvaso |
|
122.4 |
|
0.6 |
|
123.0 |
|
152.6 |
|
1.2 |
|
153.8 |
|
160.7 |
|
3.5 |
|
164.2 |
|
165.0 |
|
1.5 |
|
166.5 |
||||||||||||
Remodulin(2) |
|
107.1 |
|
23.1 |
|
130.2 |
|
111.0 |
|
28.8 |
|
139.8 |
|
106.8 |
|
18.6 |
|
125.4 |
|
98.5 |
|
19.8 |
|
118.3 |
||||||||||||
Orenitram |
|
72.4 |
|
— |
|
72.4 |
|
76.2 |
|
— |
|
76.2 |
|
85.2 |
|
— |
|
85.2 |
|
72.3 |
|
— |
|
72.3 |
||||||||||||
Unituxin |
|
42.8 |
|
1.1 |
|
43.9 |
|
48.3 |
|
4.8 |
|
53.1 |
|
44.8 |
|
10.5 |
|
55.3 |
|
42.2 |
|
7.8 |
|
50.0 |
||||||||||||
Adcirca |
|
9.6 |
|
— |
|
9.6 |
|
23.6 |
|
— |
|
23.6 |
|
14.6 |
|
— |
|
14.6 |
|
8.1 |
|
— |
|
8.1 |
||||||||||||
Other |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
||||||||||||
Total revenues |
$ |
354.3 |
$ |
24.8 |
$ |
379.1 |
$ |
411.7 |
$ |
34.8 |
$ |
446.5 |
$ |
412.1 |
$ |
32.6 |
$ |
444.7 |
$ |
386.1 |
$ |
29.1 |
$ |
415.2 |
(1) |
Net product sales include both the drug product and the respective inhalation device. |
(2) |
Net product sales include sales of infusion devices including the Remunity Pump. |
Category: Earnings
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221477756/en/
https://ir.unither.com/contact-ir
Source: